Medicine and Health Sciences Commons^™

Stilbene Analogs And Methods Of Treating Cancer, David Watt, Chunming Liu, Vitaliy M. Sviripa, Wen Zhang

Molecular and Cellular Biochemistry Faculty Patents

Stilbene analogs and pharmaceutical compositions that are useful for the treatment of various cancers, including without limitation, colorectal cancer (CRC) and breast cancer are disclosed.

For the complete abstract, please download this patent.

Mutant Insulin Degrading Enzyme And Methods Of Use, David W. Rodgers, Louis B. Hersh, Nicholas Noinaj, Eun Suk Song

Molecular and Cellular Biochemistry Faculty Patents

In one aspect, the present invention provides an isolated mutant insulin degrading enzyme (IDE) having an amino acid sequence that is at least 90% identical to SEQ ID NO:1 over its entire length and comprises at least one amino acid substitution at any of amino acid residues 332, 339, 341, 359, 360, 361, 374, 429, 609, 898, 899 or 901 of the sequence. The mutant IDE has a differential activity relative to that of wild-type IDE. Also provided is a polynucleotide encoding the polypeptide of the invention.

Single Intrathecal Administration Of The Transcription Factor Decoy Ayx1 Prevents Acute And Chronic Pain After Incisional, Inflammatory, Or Neuropathic Injury, Julien Mamet, Michael Klukinov, Tony L. Yaksh, Shelle A. Malkmus, Samantha Williams, Scott Harris, Donald C. Manning, Bradley K. Taylor, Renee R. Donahue, Frank Porreca, Jennifer Y. Xie, Janice Oyarzo, Timothy J. Brennan, Alberto Subieta, William K. Schmidt, David C. Yeomans

Renee R. Donahue

The persistence of pain after surgery increases the recovery interval from surgery to a normal quality of life. AYX1 is a DNA-decoy drug candidate designed to prevent post-surgical pain following a single intrathecal injection. Tissue injury causes a transient activation of the transcription factor EGR1 in the dorsal root ganglia–dorsal horn network, which then triggers changes in gene expression that induce neuronal hypersensitivity. AYX1 is a potent, specific inhibitor of EGR1 activity that mimics the genomic EGR1- binding sequence. Administered in the peri-operative period, AYX1 dose dependently prevents mechanical hypersensitivity in models of acute incisional (plantar), inflammatory (CFA), and chronic …